Group 1 - The core viewpoint of the article is that Minyin Capital (01141.HK) expects to achieve a consolidated net profit of approximately HKD 130 to 170 million for the fiscal year ending December 31, 2025, representing an increase of 155.9% to 234.6% compared to the previous year [1] - The previous year's consolidated net profit was HKD 50.8 million, indicating significant growth in profitability [1] - The board attributes the increase in net profit to the successful transformation and development of the group, with substantial year-on-year growth in revenue from securities underwriting, asset management, advisory services, and wealth management-related fee businesses [1]

Core Viewpoint - Minyin Capital (01141) expects to achieve a consolidated net profit of approximately HKD 130 million to HKD 170 million for the fiscal year ending December 31, 2025, representing an increase of 155.9% to 234.6% compared to last year's consolidated net profit of HKD 50.8 million [1] Group 1 - The increase in net profit is primarily attributed to the successful transformation and development of the company [1] - Significant year-on-year growth in revenue from securities underwriting, asset management, sponsorship services, and wealth management-related fee businesses contributed to the profit increase [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 民銀資本控股有限公司 CMBC CAPITAL HOLDINGS LIMITED （ 於 百 慕 達 註 冊 成 立 之 有 限 公 司 ） （股份代號：1141） 正面盈利預告 董事會認為本集團之淨利潤增加，主要歸因於本集團轉型發展顯見成效，相關年度內證 券承銷、資產管理、保薦服務和與財富管理相關的費類業務收入同比大幅增加所致。 – 1 – 於本公告日期，本公司仍在編製本集團相關年度的綜合年度業績。本公告所載資料僅基 於對本集團未經審核綜合管理賬目所作出之初步評估及董事會現時可得資料，而非基於 經本公司之獨立核數師審核或審閱或經本公司審核委員會審閱之任何數字或資料，故本 集團之實際業績或會再作出調整及變更。股東及有意投資者務請仔細閱讀預期將適時刊 發的本集團截至相關年度之年度業績公告。 股東及有意投資者於買賣本公司證券時務請審慎行事。 承董事會命 民銀資本控股有限公司 主席 李宝臣 香港，二零二六年一 ...

Group 1 - The core viewpoint of the article highlights that Minyin Capital (01141) has transferred shares from Bank of China (Hong Kong) to Fuzhong Securities, with a market value of HKD 43.36 million, representing 5.00% of the total shares [1] - Minyin Capital's mid-term performance for 2025 shows revenue of approximately HKD 245 million, reflecting a year-on-year growth of 56.66% [1] - The net profit for Minyin Capital is reported at around HKD 118 million, which indicates a year-on-year increase of 48.02% [1] - The earnings per share for Minyin Capital stands at HKD 0.1073 [1]

Group 1 - The core viewpoint of the article highlights the recent stock transfer of Minyin Capital (01141) from Bank of China (Hong Kong) to Fuzhong Securities, with a market value of HKD 43.36 million, representing 5.00% of the total shares [1] Group 2 - Minyin Capital's mid-year performance for 2025 shows revenue of approximately HKD 245 million, reflecting a year-on-year growth of 56.66% [1] - The net profit for Minyin Capital is reported at around HKD 118 million, indicating a year-on-year increase of 48.02% [1] - The earnings per share for Minyin Capital stands at HKD 0.1073 [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 民銀資本控股有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01141 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | HKD | | 0.4 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 2,500,000,000 | HKD | | 0.4 HKD | | 1,000,000,000 | 本月底法定/註冊股本總額： HKD 1,000 ...

Core Viewpoint - Ginkgo Bioworks has submitted an application for listing on the Hong Kong Stock Exchange, with CCB International and Minmetals Capital as joint sponsors [1] Group 1: Company Overview - Ginkgo Bioworks is a leading precision medicine company in China, integrating AI capabilities deeply into the biomarker value chain [1] - The company has developed a multi-omics platform that combines foundational large models with intelligent AI agents [1] Group 2: Solutions Offered - Ginkgo Bioworks provides three main solutions targeting hospitals, pharmaceutical and biotechnology companies, and medical research institutions: precision diagnostics, drug development empowerment, and clinical research and translation [1]

Group 1 - The China Securities Regulatory Commission (CSRC) has issued a notice regarding the overseas issuance and listing of shares for Baige Online (Xiamen) Digital Technology Co., Ltd., allowing the company to issue up to 45.05 million overseas listed common shares and convert approximately 118 million domestic unlisted shares for listing on the Hong Kong Stock Exchange [1] - A total of 11 shareholders are involved in the conversion of shares, with the largest shareholder, New Hope Investment Group Co., Ltd., applying for 39,854,000 shares [2] - Baige Online, established in 2015, is an insurtech company providing technology-enabled insurance intermediary services, ranking 11th in China's internet insurance intermediaries by total premium and 1st among third-party scenario internet insurance intermediaries [3] Group 2 - The company has submitted its IPO prospectus twice in 2025, with joint sponsorship from Minyin Capital and Bank of China International [2] - Baige Online's market share in the Chinese insurance market is reported to be 3.4%, indicating its significant presence in the industry [3]

公司名稱: 民銀資本控股有限公司 呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01141 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | HKD | | 0.4 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,500,000,000 | HKD | | 0.4 | HKD | | 1,000,000,000 | 本月底法定/註冊股本總額： HKD 1,000,000,000 第 1 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的 ...

Core Viewpoint - Jinyan High-tech has passed the main board listing hearing of the Hong Kong Stock Exchange, with Guoyuan International and Minyin Capital serving as joint sponsors [1] Company Overview - The company ranks fifth in the Chinese coal series calcined kaolin market, holding a market share of 5.4% based on projected 2024 revenue [1] - Jinyan High-tech is the largest producer of precision casting mullite materials in China, with a market share of 19.1% based on projected 2024 revenue [1] - The company possesses full value chain integration capabilities, covering mining, R&D, processing, production, and sales [1] Product Focus - The core products of the company are precision casting mullite materials and refractory mullite materials, which are essential components of precision casting shells and refractory materials [1] - The company has rich mineral resources, with the estimated total mineral resource of its Shuli kaolin mine being approximately 18.649 million tons [1]